Combination of High Dose Hypofractionated ...
Document type :
Compte-rendu et recension critique d'ouvrage
DOI :
PMID :
Title :
Combination of High Dose Hypofractionated Radiotherapy with Anti- PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient
Author(s) :
Milhem, Clara [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut de biologie de Lille - UMS 3702 [IBL]
Université de Lille
Institut National de la Santé et de la Recherche Médicale [INSERM]
Moralès, Olivier [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut de biologie de Lille - UMS 3702 [IBL]
Université de Lille
Institut National de la Santé et de la Recherche Médicale [INSERM]
Ingelaere, Céline [Auteur]
Institut de biologie de Lille - UMS 3702 [IBL]
Pasquier, David [Auteur]
Mordon, Serge [Auteur]
Université de Lille
Institut National de la Santé et de la Recherche Médicale [INSERM]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Mortier, Laurent [Auteur]
Mirabel, Xavier [Auteur]
Delhem, Nadira [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Université de Lille
Institut National de la Santé et de la Recherche Médicale [INSERM]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut de biologie de Lille - UMS 3702 [IBL]
Université de Lille
Institut National de la Santé et de la Recherche Médicale [INSERM]
Moralès, Olivier [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut de biologie de Lille - UMS 3702 [IBL]
Université de Lille
Institut National de la Santé et de la Recherche Médicale [INSERM]
Ingelaere, Céline [Auteur]
Institut de biologie de Lille - UMS 3702 [IBL]
Pasquier, David [Auteur]
Mordon, Serge [Auteur]
Université de Lille
Institut National de la Santé et de la Recherche Médicale [INSERM]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Mortier, Laurent [Auteur]
Mirabel, Xavier [Auteur]
Delhem, Nadira [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Université de Lille
Institut National de la Santé et de la Recherche Médicale [INSERM]
Journal title :
International Journal of Molecular Sciences
Pages :
6772
Publisher :
MDPI
Publication date :
2020-09-15
ISSN :
1661-6596
English keyword(s) :
stereotaxic radiotherapy
immunotherapy
anti-PD1
melanoma
immune response
immunotherapy
anti-PD1
melanoma
immune response
HAL domain(s) :
Sciences du Vivant [q-bio]
Sciences du Vivant [q-bio]/Cancer
Sciences du Vivant [q-bio]/Immunologie
Sciences du Vivant [q-bio]/Cancer
Sciences du Vivant [q-bio]/Immunologie
English abstract : [en]
The development of immunotherapy has recently modified the anti-tumor therapeutic arsenal ; particularly, immune checkpoint inhibitors have led to a significant increase in overall survival. The current challenge is now ...
Show more >The development of immunotherapy has recently modified the anti-tumor therapeutic arsenal ; particularly, immune checkpoint inhibitors have led to a significant increase in overall survival. The current challenge is now to select good responder patients by identifying early biomarkers to propose therapeutic combinations that potentiate the efficacy of the therapy. Here we report the case of a 60-year-old man with superficial melanoma treated with high-dose hypo fractionated radiotherapy (H-SRT) combined with a single dose of anti-PD1 immunotherapy (Nivolumab) for a metastatic lymph node recurrence due to cancer progression. In this study, we present the results obtained regarding the activation of the Th1 immune response after H-SRT treatment followed by anti PD-1 therapeutic protocol. These results were correlated with clinical data to identify potential immunological biomarkers of treatment efficacy. This exceptional case report shows that a combination of H-SRT with a single dose of anti-PD1 immunotherapy may allow a better activation of the immune response in favor of a complete clinical response.Show less >
Show more >The development of immunotherapy has recently modified the anti-tumor therapeutic arsenal ; particularly, immune checkpoint inhibitors have led to a significant increase in overall survival. The current challenge is now to select good responder patients by identifying early biomarkers to propose therapeutic combinations that potentiate the efficacy of the therapy. Here we report the case of a 60-year-old man with superficial melanoma treated with high-dose hypo fractionated radiotherapy (H-SRT) combined with a single dose of anti-PD1 immunotherapy (Nivolumab) for a metastatic lymph node recurrence due to cancer progression. In this study, we present the results obtained regarding the activation of the Th1 immune response after H-SRT treatment followed by anti PD-1 therapeutic protocol. These results were correlated with clinical data to identify potential immunological biomarkers of treatment efficacy. This exceptional case report shows that a combination of H-SRT with a single dose of anti-PD1 immunotherapy may allow a better activation of the immune response in favor of a complete clinical response.Show less >
Language :
Anglais
Popular science :
Non
Source :
Files
- https://hal.archives-ouvertes.fr/hal-02974841/document
- Open access
- Access the document
- https://hal.archives-ouvertes.fr/hal-02974841/document
- Open access
- Access the document
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555181/pdf
- Open access
- Access the document
- https://hal.archives-ouvertes.fr/hal-02974841/document
- Open access
- Access the document
- document
- Open access
- Access the document
- COMBIN~1.pdf
- Open access
- Access the document
- Open access
- Access the document